Agritech Thymes: UK-EU SPS agreement – what does it mean for plant breeders?

Published septembre 2026

Agritech Thymes: UK-EU SPS agreement – what does it mean for plant breeders?

Since Brexit, the UK agrifood sector has faced difficulties, largely due to the requirement for additional certifications and controls, such as phytosanitary certificates and border checks. This has had a significant financial impact on UK businesses that import or export plants between the UK and the EU. In view of this, the UK and the EU are working on a Sanitary and Phytosanitary (SPS) agreement to facilitate the movement of plants and animals. The agreement will cover, among other topics, sanitary and safety rules relating to the production of agrifood products.

Several aspects of the agreement are relevant for plant breeders, including a possible unitary route to plant variety protection, alignment on genetically modified organisms, and the legal questions the agreement raises.

Heading towards unitary plant variety protection?

A recent publication by the UK government confirmed that an alignment of UK Plant Breeders’ Rights (PBRs) with EU Community Plant Variety Rights (CPVRs) is being considered, which would allow protection of plant varieties in the UK and the EU through a single right. This would considerably ease things for plant breeders, who since Brexit have had to obtain separate rights to protect new plant varieties in the EU and the UK.

While practical, the agreement could have wider impacts, as highlighted in a recent Horticultural Trades Association (HTA) stakeholder briefing note. As the HTA notes, the CPVR Regulation (EU Council Regulation (EC) No 2100/94) is included in the agreement and will therefore likely apply, either by extending the UK PVR register to include all EU rights, or by the UK adopting the EU regulation through new legislation. Either way, EU rights would provide protection in the UK, but it is unclear whether protection would extend to all CPVRs or only new grants, and what will happen to UK PBRs. This may also affect DUS testing, prompting questions on whether UK DUS reports will be recognised again in the EU, and whether UK testing capacity will be preserved.

Other implications for plant breeders

Beyond these practical questions, the HTA briefing also flags broader concerns about legal jurisdiction and UK autonomy. For instance, the recent Nador Cott v Asda case highlighted differences between the interpretation of essentially derived varieties under UK and EU laws. It will therefore matter which law applies for plant varieties in the UK once the agreement comes into force, and this remains unclear. On the autonomy point, the UK is not an EU member and so would have no vote on future changes to the CPVR Regulation, which is currently being reviewed. This means that the rules the UK aligns with now could change after the agreement takes effect without UK input.

The UK government has also indicated that it will align with EU rules on genetically modified organisms (GMOs), but that precision breeding, where the UK and the EU have taken different approaches, is subject to ongoing negotiations. This raises the question of whether the EU New Genomic Techniques Regulation, and its patent transparency provisions, will be included in the agreement.

The agreement will likely be welcomed by plant breeders and the wider agrifood sector, but many questions remain unanswered and will probably stay so until the agreement is made public. Hopefully there won’t be too long to wait as the UK government is aiming for the agreement to enter into force mid-2027.


This article was prepared by Trainee Patent Attorney, Delphine Laute-Caly.

Dernières Actus

Event - 12th novembre 2026

HGF Partners with PPTI for 'Designing Foods for Healthy Aging' Webinar

As healthy aging, metabolic health and weight management rise up the consumer agenda, food and nutrition businesses are increasingly looking beyond traditional product development and towards solutions that deliver measurable …

Détails de l'événement
Event - 15th décembre 2026

Seminar on the new EU Pharma Package and its implications for regulatory exclusivities in the EU.

We are pleased to invite you to our seminar on the new EU Pharma Package and its implications for regulatory exclusivities in the EU. Speaker: Dr Andrew Wells (Partner and …

Détails de l'événement
Event - 28th Octobre 2026

HGF Attending BMCS Antibody–Drug Conjugates 2026

HGF is pleased to announce that Dr Thomas Lonsdale, Patent Director, will be attending the BMCS Antibody–Drug Conjugates 2026 meeting, taking place on 19 November 2026 at GSK, Stevenage, UK. …

Détails de l'événement

Hsu Min Chung Recognised in IAM Global Leaders 2027

HGF is delighted to announce that Partner, Hsu Min Chung, has been recognised in the IAM Global Leaders 2027 guide, a prestigious ranking that highlights some of the world’s leading …

Lire l'article
Event - 28th octobre 2026

HGF participera à la conférence KINPA 2026

HGF a le plaisir de participer à la conférence KINPA 2026, qui se tiendra le 28 octobre à Séoul, en Corée du Sud. Reconnue comme le plus grand rassemblement coréen …

Détails de l'événement
Event - 17th - 19th novembre 2026

HGF participera à l’IPBC Asia 2026

HGF a le plaisir d’annoncer que son associée, le Dr Jennifer Uno, participera à l’IPBC Asia 2026, qui se tiendra du 17 au 19 novembre 2026 à Tokyo, au Japon. …

Détails de l'événement

HGF distingué dans le guide Chambers and Partners UK 2027

HGF a le plaisir d’annoncer une nouvelle distinction dans le guide Chambers and Partners UK 2027, avec des classements remarquables, tant pour le cabinet que pour ses collaborateurs, dans plusieurs …

Lire l'article
Event - 4th novembre 2026

IAM Navigating the UPC conference

HGF are gold sponsors of the IAM Live Navigating the UPC conference. IAM Live: Navigating the UPC returns to Paris in November bringing together over 180 industry leaders for an …

Détails de l'événement